The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

  title={The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.},
  author={Aaron S. Kesselheim and Jerry Avorn and Ameet Sarpatwari},
  volume={316 8},
IMPORTANCE The increasing cost of prescription drugs in the United States has become a source of concern for patients, prescribers, payers, and policy makers. [] Key MethodEVIDENCE We reviewed the peer-reviewed medical and health policy literature from January 2005 to July 2016 for articles addressing the sources of drug prices in the United States, the justifications and consequences of high prices, and possible solutions.

Figures and Tables from this paper

Determinants of Market Exclusivity for Prescription Drugs in the United States

The peer-reviewed medical and health policy literature was reviewed to identify studies that described the different types of patent protection and regulatory exclusivities that shield brand-name prescription drugs from competition and thus help to sustain high drug prices.

Legal Challenges to State Drug Pricing Laws

In this Viewpoint, the legal arguments that industry has raised in Maryland and Nevada are reviewed, 2 of the earliest states to encounter legal challenges to their drug price reform laws.

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending

It is indicated that there are opportunities for cost savings in generic drug markets in Europe and the United States, and governments should apply coherent supply‐ and demand‐side policies inGeneric drug markets.

Variation in Prescription Drug Prices by Retail Pharmacy Type

This study partnered with GoodRx, a Web site for drug price comparison that leverages electronic claims adjudication and its relationships with large, national pharmacy benefit managers to provide nearly real-time data on drug prices, to systematically describe cash prices across different types of retail pharmacies throughout the United States.

Rising Drug Costs for Neurologic Diseases.

Clinicians should discuss the drug's value and the associated opportunity cost with patients and have an open discussion about patients' ability to financially tolerate the treatment, and clinical- and economic-based analyses from independent groups such as the Institute for Clinical and Economic Review can help physicians understand the value of drugs.

Myths and Realities About Why Prescription Drug Prices in the United States Are So High

Prescription medications cost more in the USA than in any other developed country. The reasons for those high prices are contested between defenders of the pharmaceutical industry and critics. The

Decomposition of Expenditures for Insulins Across the Distribution Chain—Insights Into Rising Prices?

There is little debate that increasing drug costs are a substantial concern for patients and payers, and manufacturers would seem to be largely responsible for rising drug costs, but increasing list prices of drugs are partially mediated by ever-increasing discounts.

International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.

  • Leah Z RandA. Kesselheim
  • Political Science, Medicine
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2021

National trends in prescription drug expenditures and projections for 2017.

  • G. SchumockE. Li L. Vermeulen
  • Medicine, Political Science
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2017
PURPOSE Historical trends and factors likely to influence future pharmaceutical expenditures are discussed, and projections are made for drug spending in 2017 in nonfederal hospitals, clinics, and

Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States

  • M. Rodwin
  • Medicine, Political Science
    International journal of health services : planning, administration, evaluation
  • 2021
To identify pharmaceutical spending-control options for the United States, we analyzed the policies of the United Kingdom, France, and Germany, which encourage drugmakers to undertake innovations



Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the American College of Physicians.

  • H. Daniel
  • Medicine, Political Science
    Annals of internal medicine
  • 2016
Policy recommendations from the American College of Physicians to address the escalating costs of prescription drugs in the United States are reported and issues of regulatory approval, patents and intellectual property, assessment of value and cost-effectiveness, and health plan drug benefits are linked.

Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs.

It is found that depending on how prices were weighted for volume across the countries, brand-name prescription drug prices were 5-198 percent higher in the United States than in the other countries in all three study years.

Options to Promote Competitive Generics Markets in the United States.

In August, the price of the 62-year-old drug pyrimethamine (Daraprim), used to treat many potentially fatal parasitic infections, was increased practically overnight from $14 to $750 per tablet, prompting public outrage and a new round of proposals to address this issue.

Payer and Policy Maker Steps to Support Value-Based Pricing for Drugs.

Now that value-based prices can be determined for drugs, insurers and policy makers can consider steps toward a value-driven pricing system that does not require Medicare negotiation, price setting, or mandates.

Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

Pharmacy benefit design represents an important public health tool for improving patient treatment and adherence and increased cost sharing is highly correlated with reductions in pharmacy use, but the long-term consequences of benefit changes on health are still uncertain.

'Government Patent Use': A Legal Approach To Reducing Drug Spending.

It is proposed that the federal government invoke its power under an existing "government patent use" law to reduce excessive prices for important patent-protected medicines.

High-cost generic drugs--implications for patients and policymakers.

Having firm timelines in place will allow pharmaceutical companies to adjust more quickly to pricing anomalies, and to meet the GDUFA commitments to waive user fees.

Variations in time of market exclusivity among top-selling prescription drugs in the United States.

This study assessed how the market exclusivity period varied among drugs for different therapeutic areas and for other characteristics of top-selling prescription medications and obtained annual published lists of the top 200 drugs by sales.

A political history of medicare and prescription drug coverage.

Why there was a historic opportunity to add a Medicare prescription drug benefit is demonstrated and challenges to implementing an effective policy are identified.